已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

A phase 2 pivotal study of savolitinib in patients with MET -amplified gastric cancer or gastroesophageal junction adenocarcinomas.

作者
Zhi Peng,Tianshu Liu,Jufeng Wang,Rongbo Lin,Hongli Liu,Feng Ye,Aiping Zhou,Zuoxing Niu,Qiong Wang,Junhua Zhang,Enxiao Li,Yanru Qin,Xiujuan Qu,Hongli Liu,Ning Liu,Xian Luo,Jie Yu,Yongxin Ren,Songhua Fan,Lin Shen
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (16_suppl): 4011-4011
标识
DOI:10.1200/jco.2026.44.16_suppl.4011
摘要

4011 Background: MET amplification is a poor prognosis for survival in patients (pts) with gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJa). Currently no approved targeted therapy is available for MET-amplified GC/GEJa. Savolitinib is a potent and highly selective oral MET-TKI. Here we reported the primary analysis results from a pivotal phase 2 trial investigating savolitinib in MET-amplified GC/GEJa, conducted with registration intent (NCT04923932). Methods: Eligible pts had locally advanced or metastatic GC/GEJa with MET amplification (gene copy number ≥10 by FISH) and had failed ≥2 lines of prior standard therapy. Pts received savolitinib 200 mg (BW < 50 kg) or 300 mg (BW ≥50 kg) BID. The primary endpoint was ORR assessed by an Independent Review Committee (IRC) per RECIST 1.1, with a pre-specified efficacy threshold defined as the lower limit of the 95% CI of ORR exceeding 15%. Secondary endpoints mainly included DCR, DoR, TTR, PFS, OS and safety. An exploratory OS analysis was conducted in pts with MET-amplified GC/GEJa, who had previously received first-line, second-line, or later-line standard therapies, but were ineligible for study enrollment and did not receive the study drug. Plasma samples were also collected at baseline and end of treatment (EOT) for comprehensive genomic profiling using a 671-gene sequencing panel (Benrui GCP, OrigiMed). Results: As of Oct 8, 2025, 65 eligible pts were enrolled and received savolitinib. Baseline characteristics were: median age of 57.4 years, ECOG PS of 0 (13.8%) or 1 (86.2%), primary tumor sites of GC (84.6%) or GEJa (15.4%), and baseline ctDNA MET-positive rate of 64.6% (42 pts). Per the IRC assessment, ORR was 32.3% (95%CI: 21.2%, 45.1%), which exceeded the pre-specified efficacy threshold; in baseline ctDNA MET-positive pts (42 pts), IRC-assessed ORR was 45.2% (95%CI: 29.8%, 61.3%). IRC-assessed secondary efficacy endpoints were: DCR of 63.1%; mTTR of 1.4 months; mDoR of 9.7 months; and mPFS 4.0 of months. mOS was 6.9 months in the 65 treated pts, versus 4.8 months in 139 pts who received alternative treatments rather than the study drug in the exploratory OS analysis. Savolitinib-related TEAEs of Grade ≥3 occurred in 23 pts (35.4%). Exploratory ctDNA biomarker analysis showed that pts (N = 14) harboring baseline alterations in FGFR2, EGFR, PIK3CA, BRAF, or KRAS had lower ORR (14.3%, 2/14) and shorter mPFS (1.4 months). Additionally, in pts (N = 26) who provided PD/EOT samples, 12 pts developed alterations in these genes that were identified as putative acquired resistance mechanisms, and 4 pts had acquired MET mutations. Conclusions: Savolitinib showed clinical efficacy and a tolerable safety profile in pts with MET-amplified GC/GEJa who had received ≥2 lines of prior therapy, supporting it to be a future treatment option for this genetically defined population. Clinical trial information: NCT04923932 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
打打的应助被墨鱼君爱摸鱼采纳,获得10
刚刚
1秒前
hyelachan完成签到,获得积分20
1秒前
学霸业的应助被vae采纳,获得10
4秒前
迷路的慕凝完成签到 ,获得积分10
5秒前
5秒前
hyelachan发布了新的文献求助20
6秒前
完美世界的应助被大糖糕僧采纳,获得10
7秒前
黎明完成签到,获得积分20
8秒前
Whao完成签到,获得积分10
10秒前
11秒前
FashionBoy的应助被光亮雨采纳,获得10
11秒前
zengyq完成签到 ,获得积分10
13秒前
干净书双完成签到,获得积分10
13秒前
13秒前
复杂的士萧完成签到 ,获得积分10
15秒前
心系天下完成签到 ,获得积分10
16秒前
大糖糕僧发布了新的文献求助10
17秒前
Linley完成签到,获得积分10
18秒前
18秒前
小蘑菇的应助被黎明采纳,获得10
18秒前
ttang11发布了新的文献求助10
18秒前
1111发布了新的文献求助50
19秒前
zzz完成签到 ,获得积分10
23秒前
友好巧曼发布了新的文献求助10
23秒前
大糖糕僧完成签到,获得积分10
24秒前
企鹅完成签到,获得积分10
24秒前
NexusExplorer的应助被雪白书蝶采纳,获得10
25秒前
ninini发布了新的文献求助10
25秒前
洛倾颜完成签到,获得积分10
26秒前
企鹅发布了新的文献求助10
27秒前
CipherSage的应助被Bdk采纳,获得10
28秒前
皮皮小猪完成签到 ,获得积分10
30秒前
30秒前
32秒前
smy完成签到 ,获得积分10
34秒前
35秒前
Atlantis30发布了新的文献求助10
36秒前
会撒娇的思萱完成签到,获得积分10
37秒前
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179547
求助须知:如何正确求助?哪些是违规求助? 9569910
关于积分的说明 21807373
捐赠科研通 7775016
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2556999
邀请新用户注册赠送积分活动 2478760